Genetically engineered immunotoxin shows early promise in patients with B-cell malignancies
Friday, March 13, 2015 - 09:30
in Health & Medicine
DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data.